Pharmaceutical Executive February 2013

February 2013 | Volume 0, Issue 0
From the Editor
Today's most important public health story is the advance in our understanding of the biology of cancer, writes Pharm Exec Editor-in-Chief William Looney.
By Pharmaceutical Executive Editors
After a decade of strife, the dialogue between industry and government appears to have entered a positive new phase. Julian Upton reports.
"Drug Life Optimization" can wrest more value through strategies that build a drug's brand franchise through its entire lifespan, according to Stan Bernard.
Pharm Exec recently convened a cross-section of industry experts to review current and pending efforts to turn great science into good oncology practice.
More new medicines gained market approval in 2012, but marketers face resistance from payers looking to cut healthcare spending, writes Jill Wechsler.
After years of asking questions, the National Highway Traffic Safety Administration (NHTSA) is moving closer to a protocol "for assessing the driving-impairment risks of drugs". Ben Comer reports.
By Pharmaceutical Executive Editors
Caronia decision shows the staying power of Sorrell v. IMS Health.
Country Report
By Pharmaceutical Executive Editors
In some ways the Australian medicines industry is going through the same restructuring and challenges as the industry is globally: the country is dealing with patent cliffs, companies are cutting back staff, an ageing population forces the government to rethink healthcare expenditures, and big originator companies are reforming.
lorem ipsum